Lixte Biotechnology Holdings Inc News - LIXTW

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif...

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the...

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb...

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW...

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the...

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer PASADENA, CA, Oct. 16, 2023...

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”...

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Biotechnology Veteran Bas van der Baan Brings Precision Oncology Expertise; Founder John S. Kovach Named...

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a...

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW...

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW...

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Results Provide Striking Molecular Evidence that Inhibiting PP2A with LB-100 Sensitizes Cancer Cells to...

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the...

WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....

WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of the follow-on offering for...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Lixte Biotechnology Holdings Inc (LIXTW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

LIXTW News

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....

LIXTW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Lixte Biotechnology Holdings Inc (LIXTW) News

Lixte Biotechnology Holdings Inc (LIXTW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

LIXTW News

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq

WestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....

LIXTW Discussion

Your Recent History